• 14786 Citations
1981 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

My interest is in clinical cancer research. I am interested in new drug development, particularly as it relates to prostate, kidney, colon and pancreatic cancer. I am also interested in clinical trials, and involved in fellowship education, along with innovative trial design.

Areas of Clinical Interest

Diagnosis of tumors, renal cell carcinoma, RCC, pancreatic cancer, pancreas, cholangiocarcinoma, prostate cancer, colon cancer, bladder cancer, rectal carcinoma, immunotherapy, chemotherapy, GI cancer, GU cancer

Fingerprint Dive into the research topics where Joel Picus is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Cell-free DNA alterations in the AR enhancer and locus predict resistance to AR-directed therapy in patients with metastatic prostate cancer

Dang, H., Chauhan, P. S., Ellis, H., Feng, W., Harris, P. K., Smith, G., Qiao, M., Dienstbach, K., Beck, R., Atkocius, A., Qaium, F., Luo, J., Michalski, J., Picus, J., Pachynski, R., Maher, C. & Chaudhuri, A. A., 2020, In : JCO Precision Oncology. 4, p. 680-713 34 p.

Research output: Contribution to journalArticle

  • 1 Scopus citations
  • Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer

    Galsky, M. D., Mortazavi, A., Milowsky, M. I., George, S., Gupta, S., Fleming, M. T., Dang, L. H., Geynisman, D. M., Walling, R., Alter, R. S., Kassar, M., Wang, J., Gupta, S., Davis, N., Picus, J., Philips, G., Quinn, D. I., Haines, G. K., Hahn, N. M., Zhao, Q. & 2 others, Yu, M. & Pal, S. K., Jun 1 2020, In : Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38, 16, p. 1797-1806 10 p.

    Research output: Contribution to journalArticle

  • 4 Scopus citations
    Open Access
  • 7 Scopus citations

    Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial

    George, D. J., Hessel, C., Halabi, S., Michaelson, M. D., Hahn, O., Walsh, M., Picus, J., Small, E. J., Dakhil, S., Feldman, D. R., Mangeshkar, M., Scheffold, C., Morris, M. J. & Choueiri, T. K., Nov 1 2019, In : Oncologist. 24, 11, p. 1497-1501 5 p.

    Research output: Contribution to journalArticle

    Open Access
  • 1 Scopus citations